Please wait a minute...
文章检索
预防医学  2021, Vol. 33 Issue (6): 563-567    DOI: 10.19485/j.cnki.issn2096-5087.2021.06.005
  论著 本期目录 | 过刊浏览 | 高级检索 |
SLC11A1基因多态性与肺结核治疗失败的关联分析
刘亚洁1, 张燕1, 陈阳贵2, 张为胜2, 马丽2, 曹明芹1
1.新疆医科大学公共卫生学院,新疆 乌鲁木齐 830011;
2.乌鲁木齐市疾病预防控制中心
The association between SLC11A1 gene polymorphism and treatment failure of pulmonary tuberculosis
LIU Yajie*, ZHANG Yan, CHEN Yanggui, ZHANG Weisheng, MA Li, CAO Mingqin
*College of Public Health, Xinjiang Medical University, Urumqi, Xinjiang 830011,China
全文: PDF(881 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 分析溶质载体蛋白家族11A成员1(SLC11A1)基因rs17235409位点多态性与肺结核治疗失败的关联,为肺结核防治提供依据。方法 选取2019年在乌鲁木齐市疾病预防控制中心登记治疗的肺结核患者为研究对象。通过国家传染病网络直报信息系统收集患者的人口学信息、临床特征和治疗信息,采用荧光多重连接酶反应技术检测SLC11A1基因rs17235409位点多态性,并进行哈迪-温伯格平衡检验,采用多因素Logistic回归模型分析rs17235409位点与肺结核治疗结局的关联。结果 纳入肺结核患者731例,治疗失败37例,治疗失败率为5.06%。rs17235409位点G/A基因型和G/G基因型患者治疗失败率分别为8.55%和4.23%。多因素Logistic回归分析结果显示,rs17235409位点G/A基因型患者比G/G基因型更容易出现治疗失败(OR=2.213,95%CI:1.041~4.702)。按性别分层分析显示,男性G/A基因型比G/G基因型更容易出现治疗失败(OR=2.547,95%CI:1.021~6.356)。结论 SLC11A1基因rs17235409位点多态性与肺结核治疗失败有关,携带G/A基因型的患者更容易出现治疗失败的结局。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
刘亚洁
张燕
陈阳贵
张为胜
马丽
曹明芹
关键词 肺结核溶质载体蛋白家族11A成员1基因多态性治疗结局    
AbstractObjective To analyze the association between recombinant solute carrier family 11, member 1 ( SLC11A1 ) rs17235409 polymorphism and treatment failure of pulmonary tuberculosis, so as to provide the basis for the prevention and treatment of pulmonary tuberculosis. Methods The patients with pulmonary tuberculosis registered for treatment at the Urumqi Center for Disease Control and Prevention in 2019 was recruited and collected demographic, clinical and treatment information from National Infectious Diseases Reporting System. The polymorphism of SLC11A1 rs17235409 was detected by multiple ligase chain reaction and Hardy-Weinberg balance test was performed. The multivariate logistic regression analysis was conducted for the association between rs17235409 and the treatment outcome of tuberculosis. Results A total of 731 cases of pulmonary tuberculosis patients were enrolled, and 37 cases failed, with a failure rate of 5.06%. The failure rate of the patients with G/A was 8.55%, with G/G was 4.23%. The results of multivariate logistic regression analysis showed that the patients with G/A were more likely to fail in the treatment than those with G/G ( OR=2.213, 95%CI: 1.041-4.702 ). The males with G/A were more likely to fail in the treatment than those with G/G ( OR=2.547, 95%CI: 1.021-6.356 ). Conclusion The rs17235409 polymorphism of SLC11A1 is associated with the failure of tuberculosis treatment, and the patients with G/A are more likely to fail.
Key wordspulmonary tuberculosis    recombinant solute carrier family 11, member 1    gene polymorphism    treatment outcome
收稿日期: 2020-11-25      修回日期: 2021-03-05     
中图分类号:  R521  
基金资助:国家自然科学基金项目(82060622); 国家自然科学基金委-新疆联合基金项目(U1903123)
作者简介: 刘亚洁,硕士在读,主要从事传染病流行病学工作
通信作者: 曹明芹,E-mail:cmq66@126.com   
引用本文:   
刘亚洁, 张燕, 陈阳贵, 张为胜, 马丽, 曹明芹. SLC11A1基因多态性与肺结核治疗失败的关联分析[J]. 预防医学, 2021, 33(6): 563-567.
LIU Yajie, ZHANG Yan, CHEN Yanggui, ZHANG Weisheng, MA Li, CAO Mingqin. The association between SLC11A1 gene polymorphism and treatment failure of pulmonary tuberculosis. Preventive Medicine, 2021, 33(6): 563-567.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2021.06.005      或      http://www.zjyfyxzz.com/CN/Y2021/V33/I6/563
[1] ARAVINDAN P P.Host genetics and tuberculosis: theory of genetic polymorphism and tuberculosis[J].Lung India,2019,36(3):244-252.
[2] 朱圭娜,侯怀哲,尹媛婕,等.SLC11A1基因多态性与宁夏南部人群肺结核易感性研究[J].中国防痨杂志,2017,39(10):1080-1087.
[3] KHALILULLAH S A,HARAPAN H,HASAN N A,et al.Host genome polymorphisms and tuberculosis infection: what we have to say?[J].Egypt J Chest Dis Tuberc,2014,63(1):173-185.
[4] LIU Y,ZHAO E,ZHU L,et al.3'UTR polymorphisms in NRAMP1 are associated with the susceptibility to pulmonary tuberculosis: a MOOSE-compliant meta-analysis[J/OL].Medicine(Baltimore),2019,98:e15955.[2021-03-05]. https://pubmed.ncbi.nlm.nih.gov/33101421/.DOI:10.1097/MD.0000000000015955.
[5] 中华人民共和国国家卫生健康委办公厅.中国结核病预防控制工作技术规范(2020年版) [EB/OL].(2020-04-02) [2021-03-05]. http://guide.medlive.cn/guideline/21035.
[6] GEBREZGABIHER G,ROMHA G,EJETA E,et al.Treatment outcome of tuberculosis patients under directly observed treatment short course and factors affecting outcome in southern Ethiopia: a five-year retrospective study[J/OL].PLoS One, 2016, 11(2): e050560.[2021-03-05].https://pubmed.ncbi.nlm.nih.gov/26918458/.DOI: 10.1371/journal.pone.0150560.
[7] 杨丹,文进,刘年强,等.新疆维吾尔族人群肺结核治疗结局影响因素研究[J].中国全科医学,2019,22(12):1413-1418.
[8] 郭净,刘忠达,张尊敬,等.丽水市耐多药肺结核治疗效果及影响因素分析[J].预防医学,2018,30(10):987-991.
[9] ALENE K A,VINEY K,YI H,et al.Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis[J].PLoS One,2018,13(5): e0197880. [2021-03-05].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5965863/. DOI: 10.1371/journal.pone.0197880.
[10] MELESE A,ZELEKE B.Factors associated with poor treatment outcome of tuberculosis in Debre Tabor, northwest Ethiopia[J].BMC Res Notes,2018,11(1):25.[2021-03-05].https://pubmed.ncbi.nlm.nih.gov/29335004/.DOI: 10.1186/s13104-018-3129-8.
[11] 马丽,古丽娜扎尔·艾克拜尔,陈阳贵,等.涂阳肺结核患者2月末痰菌阳性的影响因素分析[J].现代预防医学,2019,46(8):1487-1489,1493.
[12] ZENG J,XIE L,LUO H,et al.The epigenetic modifications of genes associated with tuberculosis susceptibility and implications for epi-drugs[J].Crit Rev Eukaryot Gene Expr,2015,25(4):349-362.
[13] SALINAS-DELGADO Y,GALAVIZ-HERNANDEZ C,TORAL R G,et al.The D543N polymorphism of the SLCLC11AL/NRAMP1 gene is associated with treatment failure in male patients with pulmonary tuberculosis[J].Drug Metab Pers Ther,2015,30(3):211-214.
[14] ALI M K,KARANJA S,KARAMA M.Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centres in2016-2017 in Mogadishu, Somalia[J].Pan Afr Med J,2017,28:197. [2021-03-05].https://pubmed.ncbi.nlm.nih.gov/29610635/.DOI:10.11604/pamj.2017.28.197.13439.
[15] MULUYE A B,KEBAMO S,TEKLIE T,et al.Poor treatment outcomes and its determinants among tuberculosis patients in selected health facilities in east Wollega, western Ethiopia[J].PLoS One,2018,13(10):e0206227. [2021-03-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203372/.DOI:10.1371/journal.pone.0206227.
[16] 邱玉冰,许琳,杨蕊,等.云南省成功治疗肺结核患者5年复发情况及影响因素研究[J].预防医学,2020,32(6):559-562.
[1] 王远航, 胡洁, 葛锐, 富小飞, 亓云鹏. 嘉兴市结核分枝杆菌耐药情况分析[J]. 预防医学, 2023, 35(8): 705-709.
[2] 黎燕, 雷梦婷, 王燧, 殷淑娇, 章存瑞, 李清春. 一起涉及多所学校的肺结核聚集性疫情调查[J]. 预防医学, 2023, 35(7): 607-610.
[3] 葛锐, 田敏, 侯志刚, 潘维浙, 朱国英, 冯豪. 2013—2022年嘉兴市儿童青少年肺结核发现延迟分析[J]. 预防医学, 2023, 35(12): 1089-1092.
[4] 陈可, 李锦成, 虞浩, 竺丽梅, 刘巧. 扬州市65岁及以上老年人群肺结核流行特征分析[J]. 预防医学, 2023, 35(10): 877-880.
[5] 张雅婷, 郝晓刚, 王炜, 焦仕林, 方春福, 张幸. 衢州市肺结核合并糖尿病病例特征分析[J]. 预防医学, 2023, 35(1): 57-60.
[6] 吴倩, 张钰, 刘魁, 王伟, 陈彬, 陈松华. 2016—2020年浙江省肺结核流行特征分析[J]. 预防医学, 2022, 34(5): 487-491.
[7] 王敏, 王炜, 郝晓刚, 卢美, 方春福, 刘魁, 陈松华. 衢州市60岁及以上肺结核病例特征分析[J]. 预防医学, 2022, 34(5): 492-495,502.
[8] 陈云鹏, 倪敏东, 贺天锋, 张新运, 车洋, 桑国鑫. 2015—2020年宁波市肺结核疫情时空聚集性分析[J]. 预防医学, 2022, 34(4): 375-379.
[9] 周旭, 王巧智, 万燕萍, 彭卫雄, 刘军, 黄颖, 徐祖辉. 衡阳市成功治疗的肺结核患者5年复发影响因素分析[J]. 预防医学, 2022, 34(3): 268-271.
[10] 杨天池, 李舒婷, 陈琴, 陈同, 车洋. 宁波市肺结核患者药物性肝损伤的影响因素研究[J]. 预防医学, 2022, 34(2): 114-118.
[11] 陈云鹏, 贺天锋. 2011—2020年宁波市肺结核流行特征分析[J]. 预防医学, 2022, 34(2): 176-179.
[12] 王迎丹, 高春洁, 王蕾. 5种时间序列模型预测肺结核发病比较[J]. 预防医学, 2022, 34(12): 1194-1200.
[13] 杨利, 常玥, 林海江. 2016—2021年台州市肺结核流行特征分析[J]. 预防医学, 2022, 34(11): 1150-1155.
[14] 王云霞, 郑娟娟, 张娟娟, 黄佩佩, 梅金周, 袁青. 2011—2018年宝安区肺结核患者耐多药的影响因素分析[J]. 预防医学, 2021, 33(7): 701-703.
[15] 张婷, 刘珊珊, 汪清雅, 张娅, 李建琼, 陈健. 重庆市疾控机构耐药肺结核治疗管理评价指标体系构建[J]. 预防医学, 2021, 33(6): 592-594.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed